Transition from Intravenous Epoprostenol to Intravenous Treprostinil in Pulmonary Hypertension

A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension

1996 • 2,590 citations

Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension

2002 • 1,382 citations

Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease

2000 • 1,051 citations

Reduction in Pulmonary Vascular Resistance with Long-Term Epoprostenol (Prostacyclin) Therapy in Primary Pulmonary Hypertension

1998 • 674 citations

Long-Term Prostacyclin for Pulmonary Hypertension With Associated Congenital Heart Defects

1999 • 510 citations

Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension

2003 • 230 citations

Pharmacokinetics and Steady-State Bioequivalence of Treprostinil Sodium (Remodulin®) Administered by the Intravenous and Subcutaneous Route to Normal Volunteers

2004 • 181 citations

Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study

1999 • 116 citations

Treatment of pulmonary hypertension secondary to connective tissue diseases

1999 • 103 citations

Intravenous infusion of prostacyclin sodium in man: clinical effects and influence on platelet adenosine diphosphate sensitivity and adenosine 3':5'-cyclic monophosphate levels.

1981 • 82 citations

The pharmacokinetics and pharmacodynamics of the prostacyclin analog 15AU81 in the anesthetized beagle dog

1993 • 38 citations

The effects of 15AU81, a chemically stable prostacyclin analog, on the cardiovascular and renin-angiotensis systems of anesthetized dogs

1991 • 36 citations